Form 4: Immunovant Chief Medical Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Immunovant's Chief Medical Officer, Michael Geffner, sold 2,657 shares of common stock to cover tax obligations related to the vesting of restricted stock units.
Summary
- Michael Geffner, the Chief Medical Officer of Immunovant, Inc., sold 2,657 shares of common stock on January 22, 2025.
- The shares were sold at a price of $23.59 per share.
- This sale was not a discretionary transaction but was mandated by the company to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
- The RSUs were part of a grant of 100,000 RSUs awarded on January 17, 2023, with 6,250 vesting on January 17, 2025.
- Following the transaction, Mr. Geffner beneficially owns 132,314 shares of Immunovant common stock.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation. It is neither positive nor negative for the company's outlook, but is a normal part of operations.
Industry Context
This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It does not indicate any change in the company's performance or outlook.
Comparison to Industry Standards
- The 'sell to cover' method for tax obligations is a standard practice among publicly traded companies to manage the tax implications of equity compensation for employees.
- Many companies use restricted stock units (RSUs) as part of their compensation packages, and the vesting and subsequent sale of shares to cover taxes is a common occurrence.
- The number of shares sold and the price are consistent with the vesting schedule and market price at the time of the transaction.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
- The sale does not indicate any change in the company's performance or outlook.
Key Dates
| Date | Description |
|---|---|
| 01/17/2023 | Date of the original grant of 100,000 restricted stock units (RSUs). |
| 01/17/2025 | Date when 6,250 of the granted RSUs vested. |
| 01/22/2025 | Date of the stock sale by Michael Geffner to cover tax obligations. |
| 01/24/2025 | Date of the signature on the Form 4 filing. |
Keywords
Immunovant, Michael Geffner, Chief Medical Officer, stock sale, restricted stock units, RSUs, tax withholding, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.